Corbus Pharmaceuticals CEO to Present at Oppenheimer Healthcare Conference
Event summary
- Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals, will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.
- The event will include a virtual presentation and one-on-one investor meetings.
- Corbus focuses on oncology and obesity with a pipeline including CRB-701, CRB-601, and CRB-913.
- The presentation is scheduled for 3:20 PM Eastern Time.
The big picture
Corbus Pharmaceuticals' participation in the Oppenheimer Healthcare Life Sciences Conference underscores its focus on advancing its clinical-stage pipeline in oncology and obesity. The event provides a platform for the company to showcase its scientific approaches and engage with potential investors, which is critical for securing funding and partnerships in the highly competitive biotech sector. The strategic emphasis on well-understood biological pathways positions Corbus to potentially capitalize on emerging trends in targeted therapies and metabolic treatments.
What we're watching
- Pipeline Progress
- How Corbus's updates on CRB-701, CRB-601, and CRB-913 will impact investor confidence.
- Market Positioning
- Whether Corbus can differentiate itself in the competitive oncology and obesity markets.
- Investor Sentiment
- The pace at which Corbus can attract new investors following the conference presentation.
Our editorial coverage:
Related topics